WO2022220045A1 - Composition for oral cavity - Google Patents

Composition for oral cavity Download PDF

Info

Publication number
WO2022220045A1
WO2022220045A1 PCT/JP2022/013661 JP2022013661W WO2022220045A1 WO 2022220045 A1 WO2022220045 A1 WO 2022220045A1 JP 2022013661 W JP2022013661 W JP 2022013661W WO 2022220045 A1 WO2022220045 A1 WO 2022220045A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoterpene
weight
oral composition
composition
oral
Prior art date
Application number
PCT/JP2022/013661
Other languages
French (fr)
Japanese (ja)
Inventor
忠杜 渋谷
Original Assignee
小林製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 小林製薬株式会社 filed Critical 小林製薬株式会社
Publication of WO2022220045A1 publication Critical patent/WO2022220045A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to an oral composition containing a phenolic compound and having reduced irritation perceived when applied to the oral cavity.
  • Thymol (2-isopropyl-5-methylphenol) is known to permeate biofilms and exhibit bactericidal action, and is widely used in oral compositions such as dentifrices and mouthwashes.
  • Paraoxybenzoic acid esters are also widely used in oral compositions as preservatives.
  • Various reports have hitherto been made on formulation techniques for oral compositions containing phenolic compounds such as thymol and paraoxybenzoic acid esters.
  • Patent Document 1 a phenolic fungicide such as thymol or paraoxybenzoic acid ester, an anionic surfactant, and a nonionic surfactant are contained, and a nonionic interface to the anionic surfactant
  • An oral composition having a weight ratio of the active agent of 0.1 to 3 and a water content of 40% by weight or less prevents the phenolic disinfectant from adsorbing to the container, and prevents the phenolic disinfectant from It is described that the aging stability of is improved.
  • oral compositions containing phenolic compounds such as thymol and paraoxybenzoic acid esters have the drawback of causing irritation when applied to the oral cavity and reducing the feeling of use.
  • a method for reducing the irritation of oral compositions containing phenolic compounds a method of blending a sweetener such as saccharin sodium, stevia extract, erythritol, etc. as a taste masking agent is known.
  • a sweetener such as saccharin sodium, stevia extract, erythritol, etc.
  • an oral composition containing such a taste masking agent exhibits a sweet taste, and does not always give a satisfactory feeling during use.
  • An object of the present invention is to provide an oral composition that contains a phenolic compound and that suppresses irritation perceived when applied to the oral cavity.
  • the present inventors have made extensive studies to solve the above problems, and found that by including a monoterpene together with a phenolic compound in an oral composition, irritation caused by the phenolic compound can be suppressed.
  • the present invention has been completed through further studies based on such findings.
  • Section 1 An oral composition comprising a phenolic compound and a monoterpene.
  • Section 2. Item 2. The oral composition according to Item 1, wherein the phenol compound is thymol and/or paraoxybenzoic acid ester.
  • Item 3. Item 3.
  • Section 4. Item 4. The oral composition according to any one of items 1 to 3, wherein the monoterpene is contained in an amount of 0.01 to 100 parts by weight per 1 part by weight of the total amount of the phenolic compound.
  • Item 5. Item 5.
  • Item 5. The oral composition according to any one of Items 1 to 4, wherein the content of the monoterpene compound is 0.001 to 5% by weight.
  • Item 7. A method for suppressing irritation of an oral composition containing a phenolic compound, comprising: A method for suppressing irritation, comprising adding a phenolic compound and a monoterpene to an oral composition.
  • the present invention by including a monoterpene together with a phenol compound in the oral cavity composition, it is possible to suppress the stimulation of the phenol compound when applied to the oral cavity, and to provide an excellent feeling of use.
  • composition of the present invention is characterized by containing a phenolic compound and a monoterpene.
  • the composition for oral cavity of the present invention is described in detail below.
  • the oral composition of the present invention contains a phenolic compound.
  • a phenol compound is a general term for compounds having a phenol skeleton.
  • the type of phenol compound used in the present invention is not particularly limited as long as it is applicable to the oral cavity, but examples include thymol, paraoxybenzoic acid ester, and the like.
  • paraoxybenzoic acid esters include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, isopropyl parahydroxybenzoate, and butyl parahydroxybenzoate.
  • phenol compounds may be used singly or in combination of two or more.
  • phenol compounds thymol, methyl parahydroxybenzoate, and ethyl parahydroxybenzoate are preferred.
  • the content of the phenolic compounds in the oral composition of the present invention may be appropriately set according to the type of phenolic compounds used, the form of the oral composition, etc.
  • the total amount of phenolic compounds is 0.001. ⁇ 5% by weight.
  • the total amount of phenolic compounds in the oral cavity composition of the present invention is preferably 0.005 to 2% by weight, more preferably 0.01 to 1% by weight, More preferably 0.05 to 0.3% by weight is mentioned.
  • the oral compositions of the present invention contain monoterpenes in addition to phenolic compounds.
  • the coexistence of a phenol compound and a monoterpene makes it possible to suppress the stimulation of the phenol compound.
  • a monoterpene is a known component that has a structure containing two isoprene units in its molecule and has a cooling effect.
  • the type of monoterpene used in the present invention is not particularly limited as long as it can be applied in the oral cavity.
  • Aldehyde monoterpenes such as citral, citronellal, perillaldehyde and safranal; ketone monoterpenes such as camphor, menthone, carbomentone and ionone; These monoterpenes may be d-, l-, or dl-forms when optical isomers are present. These monoterpenes may be used singly or in combination of two or more.
  • the monoterpene may be used in the form of an essential oil containing monoterpene.
  • the essential oil containing monoterpene can be appropriately selected from known ones and used.
  • Examples of essential oils containing menthol include peppermint oil, peppermint oil, and spearmint oil.
  • the description about the content and ratio of monoterpene in this specification is the value converted into the amount of monoterpene contained in the said essential oil, when using the essential oil containing a monoterpene.
  • These monoterpenes may be used singly or in combination of two or more.
  • ketone-based monoterpenes ketone-based monoterpenes, alcohol-based monoterpenes, and still more preferably camphor and menthol are preferred from the viewpoint of more effectively suppressing the irritation of phenolic compounds.
  • the ratio of monoterpene to phenolic compound may be appropriately set according to the type of phenolic compound and monoterpene used.
  • the total amount of monoterpene is 0.01 to 100 parts by weight.
  • the total amount of monoterpene per 1 part by weight of the total amount of phenolic compounds is preferably 0.1 to 30 parts by weight, more preferably 0.5 to 20 parts by weight. parts, more preferably 1 to 10 parts by weight.
  • the content of monoterpene in the oral composition of the present invention is, for example, 0.001 to 5% by weight. From the viewpoint of more effectively suppressing the stimulation of phenolic compounds, the content of monoterpene in the oral cavity composition of the present invention is preferably 0.01 to 3% by weight, more preferably 0.05 to 2% by weight. %, more preferably 0.1 to 1% by weight.
  • the oral composition of the present invention may further contain a monohydric lower alcohol.
  • the monohydric lower alcohol is not particularly limited as long as it can be applied in the oral cavity. mentioned. Among these monohydric lower alcohols, ethanol is preferred. These monohydric lower alcohols may be used singly or in combination of two or more.
  • the oral composition of the present invention contains a monohydric lower alcohol
  • the content is not particularly limited, but is, for example, 0.01 to 5% by weight, preferably 0.1 to 4% by weight, and more preferably. is 0.5 to 3% by weight.
  • the oral composition of the present invention may further contain a polyhydric alcohol.
  • Polyhydric alcohols are not particularly limited as long as they are applicable in the oral cavity, but examples include ethylene glycol, 1,3-butylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, polypropylene glycol, glycerin and the like. Among these polyhydric alcohols, glycerin is preferred. These polyhydric alcohols may be used singly or in combination of two or more.
  • the oral composition of the present invention contains a polyhydric alcohol
  • the content is not particularly limited, but is, for example, 0.1 to 50% by weight, preferably 1 to 40% by weight, more preferably 10 to 50% by weight. 35% by weight.
  • the oral composition of the present invention preferably contains water as a base.
  • the content of water in the composition for oral use of the present invention may be the remainder excluding the components to be added, and is appropriately set according to the form of the composition for oral use, for example, 10 to 99.9. % by weight, preferably 15 to 99% by weight, more preferably 35 to 98% by weight, and even more preferably 40 to 88% by weight.
  • the oral composition of the present invention may contain components commonly used in the art according to the form of the oral composition within a range that does not impair the effects of the present invention. good.
  • Such components include, for example, antiseptics, disinfectants, antibacterial agents, antiphlogistic agents, abrasives, glucosyltransferase (GTase) inhibitors, plaque inhibitors, hypersensitivity inhibitors, anticalculus agents, dentin strengthening/regenerating agents. Calcifying agents, local anesthetics, blood circulation promoters, thickeners, humectants, sweeteners, pigments, deodorants, pH adjusters and the like.
  • the dosage form of the oral composition of the present invention is not particularly limited as long as it can be applied to the oral cavity, and examples thereof include liquid or semi-solid forms (gel, paste).
  • the form of the oral composition of the present invention is not particularly limited as long as it can be applied to the oral cavity and stay in the oral cavity for a certain period of time.
  • Dentifrices and mouthwashes are generally referred to as mouthrinses, mouthwashes, dental rinses, etc.), mouth fresheners (mouthsprays, etc.), and oral hygiene agents such as oral ointments.
  • mouthrinses mouthwashes
  • dental rinses, etc. mouth fresheners
  • oral hygiene agents such as oral ointments.
  • liquid dentifrices, toothpastes, and mouthwashes are preferred.
  • the present invention further provides a method for suppressing irritation of an oral composition containing a phenolic compound, comprising blending a phenolic compound and a monoterpene into the oral composition.
  • the type and amount of the phenol compound, the type and amount of the monoterpene, other components that can be blended and their amount, pH, oral dosage form, form, etc. are as described in "1. Composition” column.
  • Liquid formulations having the compositions shown in Tables 1 and 2 were prepared according to a conventional method. 500 ⁇ l of the resulting liquid preparation was placed in the mouth of an evaluator who had been trained in taste testing, and irritation was evaluated according to the following criteria. ⁇ Irritation Criteria> 6: No tingling sensation is felt on the tongue. 5: Almost no tingling sensation is felt on the tongue. 4: A slight tingling sensation is felt on the tongue after about 10 seconds have passed since putting it in the mouth. 3: A tingling sensation is felt on the tongue when about 5 seconds have passed since putting it in the mouth. 2: A tingling sensation is felt on the tongue about 2 to 3 seconds after putting it in the mouth. 1: A tingling sensation is felt on the tongue immediately after putting it in the mouth.
  • Production Example A toothpaste having the composition shown in Table 3 and a mouthwash having the composition shown in Table 4 were prepared.
  • the obtained toothpaste and mouthwash were used to confirm the irritation, and both of them showed reduced irritation caused by the phenolic compound.

Abstract

[Problem] The purpose of the present invention is to provide a composition for the oral cavity that, while containing a phenol compound, exhibits a suppression of the irritation perceived upon use in the oral cavity. [Solution] The irritation caused by phenol compounds can be suppressed by the incorporation in the composition for the oral cavity of a monoterpene in addition to the phenol compound.

Description

口腔用組成物oral composition
　本発明は、フェノール化合物を含み、口腔内に適用した際に知覚される刺激が抑制されている口腔用組成物に関する。 The present invention relates to an oral composition containing a phenolic compound and having reduced irritation perceived when applied to the oral cavity.
　チモール（2-イソプロピル-5-メチルフェノール）は、バイオフィルムに浸透して殺菌作用を示すことが知られており、歯磨剤や洗口剤等の口腔用組成物に広く使用されている。また、パラオキシ安息香酸エステルは、防腐剤として口腔用組成物に広く使用されている。従来、チモールやパラオキシ安息香酸エステル等のフェノール化合物を含む口腔用組成物の製剤技術について種々報告されている。例えば、特許文献１には、チモールやパラオキシ安息香酸エステル等のフェノール系殺菌剤と、アニオン性界面活性剤と、非イオン性界面活性剤とを含有し、アニオン性界面活性剤に対する非イオン性界面活性剤の重量比が０．１～３であり、且つ、組成物中の水分含量が４０重量％以下である口腔用組成物は、フェノール系殺菌剤の容器吸着を防止し、フェノール系殺菌剤の経日安定性が向上することが記載されている。 Thymol (2-isopropyl-5-methylphenol) is known to permeate biofilms and exhibit bactericidal action, and is widely used in oral compositions such as dentifrices and mouthwashes. Paraoxybenzoic acid esters are also widely used in oral compositions as preservatives. Various reports have hitherto been made on formulation techniques for oral compositions containing phenolic compounds such as thymol and paraoxybenzoic acid esters. For example, in Patent Document 1, a phenolic fungicide such as thymol or paraoxybenzoic acid ester, an anionic surfactant, and a nonionic surfactant are contained, and a nonionic interface to the anionic surfactant An oral composition having a weight ratio of the active agent of 0.1 to 3 and a water content of 40% by weight or less prevents the phenolic disinfectant from adsorbing to the container, and prevents the phenolic disinfectant from It is described that the aging stability of is improved.
　一方、チモールやパラオキシ安息香酸エステル等のフェノール化合物を含む口腔用組成物では、口腔内に適用した際に刺激が生じ、使用感を低下させるという欠点がある。従来、フェノール化合物を含む口腔用組成物の刺激性を低減する手法としては、サッカリンナトリウム、ステビア抽出物、エリスリトール等の甘味料を味覚マスキング剤として配合する方法が知られている。しかしながら、このような味覚マスキング剤を配合した口腔用組成物では、甘みが呈され、必ずしも満足できる使用感を得ることはできない。 On the other hand, oral compositions containing phenolic compounds such as thymol and paraoxybenzoic acid esters have the drawback of causing irritation when applied to the oral cavity and reducing the feeling of use. Conventionally, as a method for reducing the irritation of oral compositions containing phenolic compounds, a method of blending a sweetener such as saccharin sodium, stevia extract, erythritol, etc. as a taste masking agent is known. However, an oral composition containing such a taste masking agent exhibits a sweet taste, and does not always give a satisfactory feeling during use.
特開平１１－３２２５５４号公報JP-A-11-322554
　本発明の目的は、フェノール化合物を含みながらも、口腔内に適用した際に知覚される刺激が抑制されている口腔用組成物を提供することである。 An object of the present invention is to provide an oral composition that contains a phenolic compound and that suppresses irritation perceived when applied to the oral cavity.
　本発明者は、前記課題を解決すべく鋭意検討を行ったところ、口腔用組成物において、フェノール化合物と共にモノテルペンを含有させることにより、フェノール化合物に起因する刺激を抑制できることを見出した。本発明は、かかる知見に基づいて、更に検討を重ねることにより完成したものである。 The present inventors have made extensive studies to solve the above problems, and found that by including a monoterpene together with a phenolic compound in an oral composition, irritation caused by the phenolic compound can be suppressed. The present invention has been completed through further studies based on such findings.
　即ち、本発明は、以下に掲げる態様の発明を提供する。
項１．　フェノール化合物、及びモノテルペンを含有する、口腔用組成物。
項２．　前記フェノール化合物が、チモール及び／又はパラオキシ安息香酸エステルである、項１に記載の口腔用組成物。
項３．　前記モノテルペンが、カンフル及び／又はメントールである、項１又は２に記載の口腔用組成物。
項４．　前記フェノール化合物の総量１重量部当たり、前記モノテルペンが０．０１～１００重量部含まれる、項１～３のいずれかに記載の口腔用組成物。
項５．　前記フェノール化合物の含有量が０．００１～５重量％である、項１～４のいずれかに記載の口腔用組成物。
項６．　前記モノテルペン化合物の含有量が０．００１～５重量％である、項１～４のいずれかに記載の口腔用組成物。
項７．　フェノール化合物を含む口腔用組成物の刺激を抑制する方法であって、
　口腔用組成物に、フェノール化合物及びモノテルペンを配合する、刺激抑制方法。 That is, the present invention provides inventions in the following aspects.
Section 1. An oral composition comprising a phenolic compound and a monoterpene.
Section 2. Item 2. The oral composition according to Item 1, wherein the phenol compound is thymol and/or paraoxybenzoic acid ester.
Item 3. Item 3. The oral composition according to Item 1 or 2, wherein the monoterpene is camphor and/or menthol.
Section 4. Item 4. The oral composition according to any one of items 1 to 3, wherein the monoterpene is contained in an amount of 0.01 to 100 parts by weight per 1 part by weight of the total amount of the phenolic compound.
Item 5. Item 5. The oral cavity composition according to any one of Items 1 to 4, wherein the content of the phenol compound is 0.001 to 5% by weight.
Item 6. Item 5. The oral composition according to any one of Items 1 to 4, wherein the content of the monoterpene compound is 0.001 to 5% by weight.
Item 7. A method for suppressing irritation of an oral composition containing a phenolic compound, comprising:
A method for suppressing irritation, comprising adding a phenolic compound and a monoterpene to an oral composition.
　本発明によれば、口腔用組成物にフェノール化合物と共にモノテルペンを含有させることにより、口腔内に適用した際にフェノール化合物の刺激を抑制でき、優れた使用感を与えることができる。 According to the present invention, by including a monoterpene together with a phenol compound in the oral cavity composition, it is possible to suppress the stimulation of the phenol compound when applied to the oral cavity, and to provide an excellent feeling of use.
１．口腔用組成物
　本発明の口腔用組成物は、フェノール化合物、及び並びにモノテルペンを含有することを特徴とする。以下、本発明の口腔用組成物について詳述する。 1. Oral Composition The oral composition of the present invention is characterized by containing a phenolic compound and a monoterpene. The composition for oral cavity of the present invention is described in detail below.
［フェノール化合物］
　本発明の口腔用組成物は、フェノール化合物を含有する。本明細書において、フェノール化合物とは、フェノール骨格を有する化合物の総称である。 [Phenolic compound]
The oral composition of the present invention contains a phenolic compound. As used herein, a phenol compound is a general term for compounds having a phenol skeleton.
　本発明で使用されるフェノール化合物の種類については、口腔内に適用可能であることを限度として特に制限されないが、例えば、チモール、パラオキシ安息香酸エステル等が挙げられる。 The type of phenol compound used in the present invention is not particularly limited as long as it is applicable to the oral cavity, but examples include thymol, paraoxybenzoic acid ester, and the like.
　パラオキシ安息香酸エステルとしては、具体的には、パラオキシ安息香酸メチル、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸イソプロピル、パラオキシ安息香酸ブチル等が挙げられる。 Specific examples of paraoxybenzoic acid esters include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, isopropyl parahydroxybenzoate, and butyl parahydroxybenzoate.
　これらのフェノール化合物は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These phenol compounds may be used singly or in combination of two or more.
　これらのフェノール化合物の中でも、好ましくはチモール、パラオキシ安息香酸メチル、パラオキシ安息香酸エチルが挙げられる。 Among these phenol compounds, thymol, methyl parahydroxybenzoate, and ethyl parahydroxybenzoate are preferred.
　本発明の口腔用組成物におけるフェノール化合物の含有量については、使用するフェノール化合物の種類、口腔用組成物の形態等に応じて適宜設定すればよいが、例えば、フェノール化合物の総量で０．００１～５重量％が挙げられる。フェノール化合物の刺激をより一層効果的に抑制するという観点から、本発明の口腔用組成物におけるフェノール化合物が総量で、好ましくは０．００５～２重量％、より好ましく０．０１～１重量％、更に好ましくは０．０５～０．３重量％が挙げられる。 The content of the phenolic compounds in the oral composition of the present invention may be appropriately set according to the type of phenolic compounds used, the form of the oral composition, etc. For example, the total amount of phenolic compounds is 0.001. ~5% by weight. From the viewpoint of more effectively suppressing the stimulation of phenolic compounds, the total amount of phenolic compounds in the oral cavity composition of the present invention is preferably 0.005 to 2% by weight, more preferably 0.01 to 1% by weight, More preferably 0.05 to 0.3% by weight is mentioned.
［モノテルペン］
　本発明の口腔用組成物は、フェノール化合物に加えて、モノテルペンを含有する。フェノール化合物とモノテルペンを共存させることにより、フェノール化合物の刺激を抑制することが可能になる。 [Monoterpene]
The oral compositions of the present invention contain monoterpenes in addition to phenolic compounds. The coexistence of a phenol compound and a monoterpene makes it possible to suppress the stimulation of the phenol compound.
　モノテルペンとは、分子内にイソプレン単位が２個含まれる構造を有し、清涼化作用等を有する公知の成分である。 A monoterpene is a known component that has a structure containing two isoprene units in its molecule and has a cooling effect.
　本発明で使用されるモノテルペンの種類については、口腔内に適用可能であることを限度として、特に制限されないが、例えば、メントール、ゲラニオール、リナロール、ボルネオール、シネオール、テルピネオール等のアルコール系モノテルペン；シトラール、シトロネラール、ペリルアルデヒド、サフラナール等のアルデヒド系モノテルペン；カンフル、メントン、カルボメントン、ヨノン等のケトン系モノテルペン等が挙げられる。これらのモノテルペンは、光学異性体が存在する場合には、ｄ体、ｌ体、ｄｌ体のいずれであってもよい。これらのモノテルペンは、１種単独で使用してもよく、２種以上を組み合わせて使用してもよい。 The type of monoterpene used in the present invention is not particularly limited as long as it can be applied in the oral cavity. Aldehyde monoterpenes such as citral, citronellal, perillaldehyde and safranal; ketone monoterpenes such as camphor, menthone, carbomentone and ionone; These monoterpenes may be d-, l-, or dl-forms when optical isomers are present. These monoterpenes may be used singly or in combination of two or more.
　また、本発明の口腔用組成物において、モノテルペンとして、モノテルペンを含む精油の状態で使用してもよい。モノテルペンを含む精油は、公知のものから適宜選択して使用することができるが、例えば、メントールを含む精油としては、ハッカ油、ペパーミント油、スペアミント油等が挙げられる。なお、本明細書におけるモノテルペンの含有量や比率に関する記載は、モノテルペンを含む精油を使用する場合は、当該精油に含まれるモノテルペン量に換算した値である。 In addition, in the composition for oral cavity of the present invention, the monoterpene may be used in the form of an essential oil containing monoterpene. The essential oil containing monoterpene can be appropriately selected from known ones and used. Examples of essential oils containing menthol include peppermint oil, peppermint oil, and spearmint oil. In addition, the description about the content and ratio of monoterpene in this specification is the value converted into the amount of monoterpene contained in the said essential oil, when using the essential oil containing a monoterpene.
　これらのモノテルペンは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These monoterpenes may be used singly or in combination of two or more.
　これらのモノテルペンの中でも、フェノール化合物の刺激をより一層効果的に抑制するという観点から、好ましくはケトン系モノテルペン、アルコール系モノテルペン、更より好ましくはカンフル、メントールが挙げられる。 Among these monoterpenes, ketone-based monoterpenes, alcohol-based monoterpenes, and still more preferably camphor and menthol are preferred from the viewpoint of more effectively suppressing the irritation of phenolic compounds.
　本発明の口腔用組成物において、フェノール化合物に対すモノテルペンの比率については、使用するフェノール化合物及びモノテルペンの種類等に応じて適宜設定すればよいが、例えば、フェノール化合物の総量１重量部当たり、モノテルペンが総量で０．０１～１００重量部が挙げられる。フェノール化合物の刺激をより一層効果的に抑制するという観点から、フェノール化合物の総量１重量部当たり、モノテルペンが総量で、好ましくは０．１～３０重量部、より好ましくは０．５～２０重量部、更に好ましくは１～１０重量部が挙げられる。 In the oral cavity composition of the present invention, the ratio of monoterpene to phenolic compound may be appropriately set according to the type of phenolic compound and monoterpene used. , the total amount of monoterpene is 0.01 to 100 parts by weight. From the viewpoint of more effectively suppressing the stimulation of phenolic compounds, the total amount of monoterpene per 1 part by weight of the total amount of phenolic compounds is preferably 0.1 to 30 parts by weight, more preferably 0.5 to 20 parts by weight. parts, more preferably 1 to 10 parts by weight.
　本発明の口腔用組成物におけるモノテルペンの含有量としては、例えば、０．００１～５重量％が挙げられる。フェノール化合物の刺激をより一層効果的に抑制するという観点から、本発明の口腔用組成物におけるモノテルペンの含有量が、好ましくは０．０１～３重量％、より好ましくは０．０５～２重量％、更に好ましくは０．１～１重量％が挙げられる。 The content of monoterpene in the oral composition of the present invention is, for example, 0.001 to 5% by weight. From the viewpoint of more effectively suppressing the stimulation of phenolic compounds, the content of monoterpene in the oral cavity composition of the present invention is preferably 0.01 to 3% by weight, more preferably 0.05 to 2% by weight. %, more preferably 0.1 to 1% by weight.
［１価低級アルコール］
　本発明の口腔用組成物は、更に１価低級アルコールを含んでいてもよい。１価低級アルコールとしては、口腔内に適用可能であることを限度として、特に制限されないが、例えば、炭素数２～５の１価アルコール、具体的には、エタノール、プロパノール、イソプロパノール、ブタノール等が挙げられる。これらの１価低級アルコールの中でも、好ましくはエタノールが挙げられる。これらの１価低級アルコールは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 [Monohydric lower alcohol]
The oral composition of the present invention may further contain a monohydric lower alcohol. The monohydric lower alcohol is not particularly limited as long as it can be applied in the oral cavity. mentioned. Among these monohydric lower alcohols, ethanol is preferred. These monohydric lower alcohols may be used singly or in combination of two or more.
　本発明の口腔用組成物に１価低級アルコールを含有させる場合、その含有量については、特に制限されないが、例えば、０．０１～５重量％、好ましくは０．１～４重量％、更に好ましくは０．５～３重量％が挙げられる。 When the oral composition of the present invention contains a monohydric lower alcohol, the content is not particularly limited, but is, for example, 0.01 to 5% by weight, preferably 0.1 to 4% by weight, and more preferably. is 0.5 to 3% by weight.
［多価アルコール］
　本発明の口腔用組成物は、更に多価アルコールを含んでいてもよい。多価アルコールについては、口腔内に適用可能であることを限度として、特に制限されないが、例えば、エチレングリコール、１，３－ブチレングリコール、プロピレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール、ポリプロピレングリコール、グリセリン等が挙げられる。これらの多価アルコールの中でも、好ましくはグリセリンが挙げられる。これらの多価アルコールは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 [Polyhydric alcohol]
The oral composition of the present invention may further contain a polyhydric alcohol. Polyhydric alcohols are not particularly limited as long as they are applicable in the oral cavity, but examples include ethylene glycol, 1,3-butylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, polypropylene glycol, glycerin and the like. Among these polyhydric alcohols, glycerin is preferred. These polyhydric alcohols may be used singly or in combination of two or more.
　本発明の口腔用組成物に多価アルコールを含有させる場合、その含有量については、特に制限されないが、例えば、０．１～５０重量％、好ましくは１～４０重量％、更に好ましくは１０～３５重量％が挙げられる。 When the oral composition of the present invention contains a polyhydric alcohol, the content is not particularly limited, but is, for example, 0.1 to 50% by weight, preferably 1 to 40% by weight, more preferably 10 to 50% by weight. 35% by weight.
［水］
　本発明の口腔用組成物は、基剤として水が含まれていることが好ましい。本発明の口腔用組成物における水の含有量については、添加する成分を除いた残部であればよく、口腔用組成物の形態等に応じて適宜設定されるが、例えば、１０～９９．９重量％、好ましくは１５～９９重量％、より好ましくは３５～９８重量％、更に好ましくは４０～８８重量％が挙げられる。 [water]
The oral composition of the present invention preferably contains water as a base. The content of water in the composition for oral use of the present invention may be the remainder excluding the components to be added, and is appropriately set according to the form of the composition for oral use, for example, 10 to 99.9. % by weight, preferably 15 to 99% by weight, more preferably 35 to 98% by weight, and even more preferably 40 to 88% by weight.
［その他の含有成分］
　本発明の口腔用組成物は、前述する成分以外に、本発明の効果を損なわない範囲で、口腔用組成物の形態に応じて、当該技術分野で通常使用される成分を含有していてもよい。このような成分としては、例えば、防腐剤、殺菌剤、抗菌剤、消炎剤、研磨剤、グルコシルトランスフェラーゼ（ＧＴａｓｅ）阻害剤、プラーク抑制剤、知覚過敏抑制剤、歯石予防剤、歯質強化／再石灰化剤、局所麻酔剤、血行促進剤、増粘剤、湿潤剤、甘味剤、色素、消臭剤、ｐＨ調整剤等が挙げられる。 [Other ingredients]
In addition to the components described above, the oral composition of the present invention may contain components commonly used in the art according to the form of the oral composition within a range that does not impair the effects of the present invention. good. Such components include, for example, antiseptics, disinfectants, antibacterial agents, antiphlogistic agents, abrasives, glucosyltransferase (GTase) inhibitors, plaque inhibitors, hypersensitivity inhibitors, anticalculus agents, dentin strengthening/regenerating agents. Calcifying agents, local anesthetics, blood circulation promoters, thickeners, humectants, sweeteners, pigments, deodorants, pH adjusters and the like.
［剤型・形態］
　本発明の口腔用組成物の剤型については、口腔内への適用が可能であることを限度として特に制限されないが、例えば、液状又は半固形状（ゲル状、ペースト状）が挙げられる。 [Dosage form/form]
The dosage form of the oral composition of the present invention is not particularly limited as long as it can be applied to the oral cavity, and examples thereof include liquid or semi-solid forms (gel, paste).
　本発明の口腔用組成物の形態については、口腔内に適用されて口腔内で一定時間滞留し得るものである限り特に制限されないが、例えば、液体歯磨剤、練歯磨剤、洗口液（液体歯磨剤、洗口液は、一般にマウスリンス、マウスウォッシュ、デンタルリンス等と呼称されることがある）、口中清涼剤（マウススプレー等）、口腔用軟膏剤等の口腔衛生剤が挙げられる。これらの中でも、好ましくは液体歯磨剤、練歯磨剤、洗口液が挙げられる。 The form of the oral composition of the present invention is not particularly limited as long as it can be applied to the oral cavity and stay in the oral cavity for a certain period of time. Dentifrices and mouthwashes are generally referred to as mouthrinses, mouthwashes, dental rinses, etc.), mouth fresheners (mouthsprays, etc.), and oral hygiene agents such as oral ointments. Among these, liquid dentifrices, toothpastes, and mouthwashes are preferred.
２．刺激抑制方法
　本発明は、更に、フェノール化合物を含む口腔用組成物の刺激を抑制する方法であって、口腔用組成物に、フェノール化合物及びモノテルペンを配合する、刺激抑制方法を提供する。 2. Method for Suppressing Irritation The present invention further provides a method for suppressing irritation of an oral composition containing a phenolic compound, comprising blending a phenolic compound and a monoterpene into the oral composition.
　本発明の刺激抑制において、フェノール化合物の種類や配合量、モノテルペンの種類や配合量、配合できる他の成分やその配合量、ｐＨ、口腔剤型、形態等については、前記「１．口腔用組成物」の欄に記載の通りである。 In the stimulation suppression of the present invention, the type and amount of the phenol compound, the type and amount of the monoterpene, other components that can be blended and their amount, pH, oral dosage form, form, etc. are as described in "1. Composition” column.
　以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 The present invention will be more specifically described below by showing Examples, but the present invention is not limited to these.
試験例
　表１及び２に示す組成の液剤を常法に従って調製した。味覚試験に関して訓練されている評価者の口に、得られた液剤５００μｌを含ませ、下記の判定基準に従って、刺激性を評価した。
＜刺激性の判定基準＞
　６：舌にピリピリとした刺激を全く感じない。
　５：舌にピリピリとした刺激を殆ど感じない。
　４：口に含ませてから１０秒程度経過した以降に、舌にピリピリとした刺激を若干感じる。
　３：口に含ませてから５秒程度経過した時点で、舌にピリピリとした刺激を感じる。
　２：口に含ませてから２～３秒程度経過した時点で、舌にピリピリとした刺激を感じる。
　１：口に含ませた直後から、舌にピリピリとした刺激を感じる。 Test Examples Liquid formulations having the compositions shown in Tables 1 and 2 were prepared according to a conventional method. 500 μl of the resulting liquid preparation was placed in the mouth of an evaluator who had been trained in taste testing, and irritation was evaluated according to the following criteria.
<Irritation Criteria>
6: No tingling sensation is felt on the tongue.
5: Almost no tingling sensation is felt on the tongue.
4: A slight tingling sensation is felt on the tongue after about 10 seconds have passed since putting it in the mouth.
3: A tingling sensation is felt on the tongue when about 5 seconds have passed since putting it in the mouth.
2: A tingling sensation is felt on the tongue about 2 to 3 seconds after putting it in the mouth.
1: A tingling sensation is felt on the tongue immediately after putting it in the mouth.
　結果を表１及び２に示す。カンフル又はメントール非存在下でチモール又はパラオキシ安息香酸エステル（パラオキシ安息香酸メチル又はパラオキシ安息香酸エチル）を含む場合には、刺激が認められた（比較例１～５）。これに対して、チモール又はパラオキシ安息香酸エステルと共にカンフル又はメントールを含む場合には、刺激を抑制できていた（実施例１～１２）。とりわけ、チモール又はパラオキシ安息香酸エステル１重量部当たり、カンフル又はメントールを１重量部以上含む場合には、刺激抑制効果が顕著に認められた（実施例２～６及び８～１２）。
　

  Results are shown in Tables 1 and 2. Irritation was observed when thymol or parahydroxybenzoate (methyl parahydroxybenzoate or ethyl parahydroxybenzoate) was included in the absence of camphor or menthol (Comparative Examples 1-5). On the other hand, when camphor or menthol was contained together with thymol or paraoxybenzoic acid ester, irritation could be suppressed (Examples 1 to 12). In particular, when 1 part by weight or more of camphor or menthol was contained per 1 part by weight of thymol or p-oxybenzoic acid ester, the irritation suppressing effect was remarkably observed (Examples 2 to 6 and 8 to 12).
Figure JPOXMLDOC01-appb-T000001
 　
Figure JPOXMLDOC01-appb-T000001
 　
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
製造例
　表３に示す組成の練歯磨剤、及び表４に示す組成の洗口液を調製した。得られた練歯磨剤及び洗口液を使用して、刺激性を確認したところ、いずれも、フェノール化合物に起因する刺激が低減されていた。
　
  Production Example A toothpaste having the composition shown in Table 3 and a mouthwash having the composition shown in Table 4 were prepared. The obtained toothpaste and mouthwash were used to confirm the irritation, and both of them showed reduced irritation caused by the phenolic compound.
Figure JPOXMLDOC01-appb-T000003
 　

 
Figure JPOXMLDOC01-appb-T000003
 　

 
Figure JPOXMLDOC01-appb-T000004
 
Figure JPOXMLDOC01-appb-T000004
 

Claims (7)

  1. 　フェノール化合物、及びモノテルペンを含有する、口腔用組成物。 An oral composition containing a phenolic compound and a monoterpene.
  2. 　前記フェノール化合物が、チモール及び／又はパラオキシ安息香酸エステルである、請求項１に記載の口腔用組成物。 The oral composition according to claim 1, wherein the phenolic compound is thymol and/or paraoxybenzoic acid ester.
  3. 　前記モノテルペンが、カンフル及び／又はメントールである、請求項１又は２に記載の口腔用組成物。 The oral composition according to claim 1 or 2, wherein the monoterpene is camphor and/or menthol.
  4. 　前記フェノール化合物の総量１重量部当たり、前記モノテルペンが０．０１～１００重量部含まれる、請求項１～３のいずれかに記載の口腔用組成物。 The oral composition according to any one of claims 1 to 3, wherein the monoterpene is contained in an amount of 0.01 to 100 parts by weight per 1 part by weight of the total amount of the phenolic compound.
  5. 　前記フェノール化合物の含有量が０．００１～５重量％である、請求項１～４のいずれかに記載の口腔用組成物。 The oral composition according to any one of claims 1 to 4, wherein the content of the phenolic compound is 0.001 to 5% by weight.
  6. 　前記モノテルペン化合物の含有量が０．００１～５重量％である、請求項１～４のいずれかに記載の口腔用組成物。 The oral composition according to any one of claims 1 to 4, wherein the content of the monoterpene compound is 0.001 to 5% by weight.
  7. 　フェノール化合物を含む口腔用組成物の刺激を抑制する方法であって、
    　口腔用組成物に、フェノール化合物及びモノテルペンを配合する、刺激抑制方法。

          A method for suppressing irritation of an oral composition containing a phenolic compound, comprising:
    A method for suppressing irritation, comprising adding a phenolic compound and a monoterpene to an oral composition.
PCT/JP2022/013661 2021-04-13 2022-03-23 Composition for oral cavity WO2022220045A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021067881A JP2022162849A (en) 2021-04-13 2021-04-13 Composition for oral cavity
JP2021-067881 2021-04-13

Publications (1)

Publication Number Publication Date
WO2022220045A1 true WO2022220045A1 (en) 2022-10-20

Family

ID=83640575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/013661 WO2022220045A1 (en) 2021-04-13 2022-03-23 Composition for oral cavity

Country Status (3)

Country Link
JP (1) JP2022162849A (en)
TW (1) TW202302067A (en)
WO (1) WO2022220045A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523355A (en) * 1998-08-24 2002-07-30 ザ、プロクター、エンド、ギャンブル、カンパニー Liquid mucoadhesive composition for oral cavity
JP2004238375A (en) * 2003-02-10 2004-08-26 Earth Chem Corp Ltd Bactericidal composition used for oral cavity
JP2007031394A (en) * 2005-07-29 2007-02-08 Lion Corp Liquid composition for oral cavity and method for preventing 1-menthol deposition
JP2008143825A (en) * 2006-12-08 2008-06-26 Lion Corp Tooth paste composition
JP2018002719A (en) * 2016-06-27 2018-01-11 サンスター株式会社 Oral composition
JP2018095574A (en) * 2016-12-09 2018-06-21 ライオン株式会社 Oral composition
JP2018100245A (en) * 2016-12-21 2018-06-28 サンスター株式会社 Composition for use in mouth and/or throat

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523355A (en) * 1998-08-24 2002-07-30 ザ、プロクター、エンド、ギャンブル、カンパニー Liquid mucoadhesive composition for oral cavity
JP2004238375A (en) * 2003-02-10 2004-08-26 Earth Chem Corp Ltd Bactericidal composition used for oral cavity
JP2007031394A (en) * 2005-07-29 2007-02-08 Lion Corp Liquid composition for oral cavity and method for preventing 1-menthol deposition
JP2008143825A (en) * 2006-12-08 2008-06-26 Lion Corp Tooth paste composition
JP2018002719A (en) * 2016-06-27 2018-01-11 サンスター株式会社 Oral composition
JP2018095574A (en) * 2016-12-09 2018-06-21 ライオン株式会社 Oral composition
JP2018100245A (en) * 2016-12-21 2018-06-28 サンスター株式会社 Composition for use in mouth and/or throat

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
1 October 1998 (1998-10-01), WARNER-LAMBERT. USA.: " Tartar Control Mouthwash ID# 10073000. ", XP009540258 *
DATABASE GNPD [online] MINTEL; MISTINE: "Peppermint Flavoured Herbal Extract Mouthwash", XP002760753, Database accession no. 2760425 *
DATABASE Mintel BIOCLIN. ITALY : " Cream Toothpaste", XP055977027, retrieved from GNPD *

Also Published As

Publication number Publication date
TW202302067A (en) 2023-01-16
JP2022162849A (en) 2022-10-25

Similar Documents

Publication Publication Date Title
JP5251350B2 (en) Dentifrice composition
JP5597970B2 (en) Dentifrice composition
WO2013094504A1 (en) Oral composition
JP2008514573A (en) Use of fragrance mixtures as active substances against bad breath
WO2016093279A1 (en) Composition for use in oral cavity
JP5493731B2 (en) Dentifrice composition
WO2011055707A1 (en) Dentifrice composition
JP6740901B2 (en) Oral composition and method for suppressing taste of cationic bactericide in oral composition
JP5842565B2 (en) Mouthwash composition and method for inhibiting discoloration in mouthwash composition
WO2005072691A1 (en) Composition for inhibiting halitosis
WO2018066341A1 (en) Oral composition and method for suppressing discoloration of formulation and liquid separation thereof
JP5825088B2 (en) Liquid oral composition
JP2019167297A (en) Dentifrice composition
WO2022220045A1 (en) Composition for oral cavity
JP6409618B2 (en) Dentifrice composition
JP4158036B2 (en) Dentifrice composition and method for producing the same
JP2009137897A (en) Dentifrice composition
WO2019107340A1 (en) Composition for oral use
JP6173735B2 (en) Dentifrice composition
AU783747B2 (en) Dentifrice compositions having reduced abrasivity
KR101773227B1 (en) Dentrifice composition
JP5471318B2 (en) Dentifrice composition
JP7172392B2 (en) oral composition
WO2016136719A1 (en) Toothpaste composition
JPWO2018151076A1 (en) Gel dentifrice composition and its stickiness inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22787970

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22787970

Country of ref document: EP

Kind code of ref document: A1